Related Experiment Video
Updated: Jul 6, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma
Miyuki Taniguchi1, Soo-Ryang Kim, Susumu Imoto
1Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan.
Aim:
To evaluate long-term follow-up of minimum-sized hepatocellular carcinoma (HCC) treated with percutaneous ethanol injection (PEI).
Methods:
PEI was applied to 42 lesions in 31 patients (23 male and eight female) with HCC < 15 mm in diameter, over the past 15 years.
Results:
Overall survival rate was 74.1% at 3 years, 49.9% at 5 years, 27.2% at 7 years and 14.5% at 10 years. These results are superior to, or at least the same as those for hepatic resection and radiofrequency ablation. Survival was affected only by liver function, but not by sex, age, etiology of Hepatitis B virus or Hepatitis C virus, alpha-fetoprotein levels, arterial and portal blood flow, histological characteristics, and tumor multiplicity or size. Patients in Child-Pugh class A and B had 5-, 7- and 10-years survival rates of 76.0%, 42.2% and 15.8%, and 17.1%, 8.6% and 0%, respectively (P = 0.025).
Conclusion:
Treatment with PEI is best indicated for patients with HCC < 15 mm in Child-Pugh class A.
